A Phase 1 interventional study of PMCC-COE-KMA in Relapsed/Refractory Multiple Myeloma, sponsored by Peter MacCallum Cancer Centre, Australia. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Peter MacCallum Cancer Centre, Australia · Phase 1, Interventional, and Treatment
The study proposed here intends to evaluate the safety and efficacy of escalating doses of autologous PMCC-COE-KMA CAR T-cells administered to patients with relapsed/refractory multiple myeloma that expresses the KMA. The PMCC-COE-KMA CAR T-cells will be produced using LV and administered to patients after lymphodepleting conditioning chemotherapy. Considering the poor prognosis of myeloma patients who have relapsed after ≥ 2 lines of therapy, combined with evidence of PMCC-COE-KMA CAR T-cell specificity, as well as the efficacy and manageable toxicity of PMCC-COE-KMA, investigators believe the potential benefits outweigh the risks of this trial.
Exclusion Criteria:
Single infusion of PMCC-COE-KMA after lymphodepletion
Biological: PMCC-COE-KMA
PMCC-COE-KMA is a cellular immunotherapy derived from autologous mononuclear cells that have undergone ex vivo modification to target KMA on the surface of cancer cells. Autologous T-cells are genetically programmed using LV transduction to express a CAR, which comprises an antigen recognition moiety liked to a T-cell receptor signalling domain. This makes the CAR T-cells capable of recognising KMA on tumour cells and triggering target cell destruction in a major histocompatibility complex-independent manner.
To evaluate the safety of autologous PMCC-COE-KMA in patients with RR MM following lymphodepletion, identifying the maximum tolerated dose (MTD)
* Incidence, nature, and severity of "moderate" toxicity (MT) events and dose limiting toxicities (DLTs) These will determine the MTD of PMCC-COE-KMA * Incidence, nature, and severity of AEs graded according to the Common Toxicity Criteria for Adverse Events, Version 5.0 (CTCAE v5.0) and the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading for CRS and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), and serious adverse events (SAEs)
Time frame: From enrollment to the first 28 days after the PMCC-COE-KMA infusion
To assess manufacturing feasibility of PMCC-COE-KMA, defined as the percentage of patients in whom a suitable product manufactured, meeting pre-determined criteria for release.
The patient has a suitable product manufactured, meeting pre-determined criteria for release (yes/no). The percentage of patients with this feasible manufacture will be reported.
Time frame: From enrollment to the first 28 days after the PMCC-COE-KMA infusion
To evaluate the efficacy of PMCC-COE-KMA, as assessed by ORR based on the International Myeloma Working Group (IMWG) response criteria
* Objective response after the PMCC-COE-KMA infusion, measured every 28 days following the infusion of PMCC-COE-KMA by IMWG criteria * Best overall response * Duration of response, defined as time from first response of stringent complete response (sCR), CR, very good partial response (VGPR) or PR to time to progressive disease (PD) by IMWG criteria (death is a censoring event), for those patients who experience a sCR, CR, VGPR or PR
Time frame: From enrollment to the followed up for 52 weeks after their PMCCCOE-KMA infusion
To evaluate the efficacy of PMCC-COE-KMA, as assessed by minimal residual disease (MRD) at defined time points
Minimal residual disease response by flow cytometry and/or molecular techniques on bone marrow aspirate at Day +28 and at suspected CR
Time frame: From enrollment to the followed up for 52 weeks after their PMCCCOE-KMA infusion
To evaluate the efficacy of PMCC-COE-KMA, as progression-free survival
Progression-free survival, defined as time from registration until biochemical, radiological and/or clinical PD or death, according to IMWG criteria. Patients without PD or death will be censored at their last time of disease assessment
Time frame: From enrollment to the followed up for 52 weeks after their PMCCCOE-KMA infusion
To evaluate the efficacy of PMCC-COE-KMA as overall survival (OS) analyses
Overall survival, defined as time from study enrolment to death. Patients without death will be censored at the earliest of the study close out date or date last seen alive
Time frame: From enrollment to the followed up for 52 weeks after their PMCCCOE-KMA infusion
To evaluate the T-cell phenotype of the PMCC-COE-KMA infusion product
Immunophenotype of the PMCC-COE-KMA infusion product by flow cytometry and/or single-cell multi-omic assays
Time frame: From enrollment to 52 weeks after their PMCCCOE-KMA infusion
To evaluate the expansion and persistence of autologous PMCC-COE-KMA in blood and bone marrow after infusion
PMCC-COE-KMA expansion and persistence kinetics in peripheral blood, as measured by flow cytometry and/or a quantitative polymerase chain reaction (PCR)
Time frame: From enrollment to 52 weeks after their PMCCCOE-KMA infusion
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peter MacCallum Cancer Centre, Australia